Same-day discharge after elective percutaneous closure of patent foramen ovale

Submitted: October 30, 2023
Accepted: December 6, 2023
Published: February 2, 2024
Abstract Views: 742
PDF_EARLY VIEW: 236
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Percutaneous closure of the patent foramen ovale (PFO) is increasingly performed in specific patients with cryptogenic stroke or clinical evidence of a paradoxical embolism. This study was performed to determine the safety of same-day discharge (SDD) following such procedures. This is a prospective, observational study of patients undergoing elective percutaneous PFO closure in a single tertiary center in Portugal between January 2020 and July 2023. AmplatzerTM devices (St. Jude Medical, St. Paul, MN, USA) and NobblestichTM EL (HeartStitch, Inc., Fountain Valley, CA, USA) were used. After 6 months, the following events were looked at: post-procedural paroxysmal atrial fibrillation, stroke, unplanned cardiac re-hospitalization, urgent cardiac surgery, major vascular complications, pericardial effusions, device embolization, and death. We studied 122 consecutive patients (52% female, 68; 48±12 years old) who had elective percutaneous closure with success and no complications. Forty-nine (40%) had SDD. AmplatzerTM devices were used more frequently in the SDD group, while NobblestichTM EL was more common in the overnight group. During the overnight group's follow-up period, there was one non-cardiovascular death; there were no further events. SDD after elective percutaneous closure of PFO was shown to be a safe and successful patient management method, including NobblestichTM, which we describe for the first time. Our results prove the safety of this same-day discharge strategy. We hypothesize that in the near future, in selected cases, PFO closure might become an ambulatory procedure.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Asbeutah AA, Junaid M, Hassan F, et al. Same day discharge after structural heart disease interventions in the era of the coronavirus-19 pandemic and beyond. World J Cardiol 2022;14:271-81. DOI: https://doi.org/10.4330/wjc.v14.i5.271
Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC guidelines for the management of adult congenital heart disease. Eur Heart J 2021;42:563-645. DOI: https://doi.org/10.15829/1560-4071-2021-4702
Prashar A, Shah S, Zhang R, et al. Safety and cost implications of same-day discharge following elective percutaneous closure of patent foramen ovale and atrial septal defects in Australia. Hearts 2021;2:543-50. DOI: https://doi.org/10.3390/hearts2040041
Paiva L, Dinis P, Providencia R, et al. Percutaneous patent foramen ovale closure: the Paradoxical cerebral embolism prevention registry. Rev Port Cardiol 2015;34:151-7. DOI: https://doi.org/10.1016/j.repce.2014.08.025
Kent DM, Dahabreh IJ, Ruthazer R, et al. Device closure of patent foramen ovale after stroke: pooled analysis of completed randomized trials. J Am Coll Cardiol 2016;67:907-17. DOI: https://doi.org/10.1016/j.jacc.2015.12.023
Pristipino C, Sievert H, D'Ascenzo F, et al. European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. Eur Heart J 2019;40:3182-95. DOI: https://doi.org/10.1093/eurheartj/ehy649
Amin Z, Boudoulas K, Carroll J, et al. SCAI guidelines for the management of patent foramen ovale. 2022. Available from: https://scai.org/publications/clinical-documents/scai-guidelines-management-patent-foramen-ovale.
Nyboe C, Olsen MS, Nielsen-Kudsk JE, Hjortdal VE. Atrial fibrillation and stroke in adult patients with atrial septal defect and the long-term effect of closure. Heart 2015;101:706-11. DOI: https://doi.org/10.1136/heartjnl-2014-306552
Amin Z, Hijazi ZM, Bass JL, et al. PFO closure complications from the AGA registry. Catheter Cardiovasc Interv 2008;72:74-9. DOI: https://doi.org/10.1002/ccd.21582
Mas JL, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med 2017;377:1011-21. DOI: https://doi.org/10.1056/NEJMoa1705915

Ethics Approval

The study was performed according to the recommendations of Helsinki Declaration. Observational study is not mandatory to be proposed to the local ethical committee.

How to Cite

Martins da Costa, Catarina, Ana Filipa Amador, Roberto Pinto, Bruno Bragança, Inês Oliveira, João Carlos Silva, and Rui André Rodrigues. 2024. “Same-Day Discharge After Elective Percutaneous Closure of Patent Foramen Ovale”. Monaldi Archives for Chest Disease, February. https://doi.org/10.4081/monaldi.2024.2833.

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.